Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX301 in advanced solid tumors
NCT05731934Phase 1Completed
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of narazaciclib in solid tumor (advanced stage), sponsored by Hanx Biopharmaceuticals. Primary endpoints: Incidence of adverse events and Incidence of Dose Limiting Toxicities. Started Sep 2020; status: completed.
02
Drugs
narazaciclib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05731934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731934.